{"id":52936,"date":"2023-01-16T13:02:27","date_gmt":"2023-01-16T12:02:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/"},"modified":"2023-01-16T13:02:27","modified_gmt":"2023-01-16T12:02:27","slug":"global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/","title":{"rendered":"Global Phase II\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5697514\/phase-iiiii-cro-benchmarking-14th-ed?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=b4p29f&amp;utm_campaign=1807956+-+Global+Phase+II%2FIII+CRO+Benchmarking+Report+2022%3A+Analysis+of+CRO+Selection+and+Share+Performance+Data+for+31+Providers+on+21+Key+Attributes&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Phase II\/III CRO Benchmarking (14th Ed.)&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230116005296\/en\/1686464\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230116005296\/en\/1686464\/21\/logo.jpg\"><\/a><\/p>\n<p>\nAlthough the landscape for outsourcing clinical research changes with each passing year, the goal of our CRO benchmarking reports remains the same: to help sponsors make educated decisions and to help CROs understand how they stack up against competitors on brand positioning and performance metrics.\n<\/p>\n<p>\n229 experienced decision-makers that select and work with Phase II\/III service providers contributed to this year&#8217;s report, representing 776 encounters between outsourcers and CROs. We analyze a variety of factors around CRO selection and share performance data for 31 providers on 21 key attributes, including budget factors, delivery factors, staff characteristics, and services.\n<\/p>\n<p>\nKnowing which attributes are important for success and understanding the strength of various brands is one part of the puzzle &#8211; but how well are CROs actually performing against expectations?\n<\/p>\n<p>\nThe bulk of this report on CRO performance is designed to help sponsors determine which providers will deliver effectively and for CROs to benchmark their performance against the industry&#8217;s quality standards. For sponsors, we are confident that this report will help you to make the right decision for your clinical development program.\n<\/p>\n<p>\nAnd for CROs, with these insights, you can design marketing materials that effectively promote your company&#8217;s service offerings.\n<\/p>\n<p>\n<strong>What you will learn:<\/strong>\n<\/p>\n<p>\n<strong>Sponsors:<\/strong>\n<\/p>\n<ul>\n<li>\nLearn which service providers your company should keep in mind for your clinical development programs by identifying how individual CROs have performed for your peers\n<\/li>\n<li>\nBetter understand CRO customer loyalty based on overall customer satisfaction, willingness to recommend, and likelihood to use again\n<\/li>\n<li>\nDiscover which Phase II\/III-specific attributes motivate outsourcing selection, and evaluate verbatim responses from recent customers on CRO performance\n<\/li>\n<\/ul>\n<p>\n<strong>CROs:<\/strong>\n<\/p>\n<ul>\n<li>\nUnderstand how recent customers have rated your company&#8217;s performance across 21 key attributes\n<\/li>\n<li>\nLearn how to improve your marketing messaging by focusing on the areas in which customers say you excel compared to the competition\n<\/li>\n<li>\nRead verbatim customer rationale for their satisfaction level with your company&#8217;s performance\n<\/li>\n<li>\nFind out which factors affect sponsor outsourcing preferences, and which factors are gaining in importance for future outsourcing\n<\/li>\n<\/ul>\n<p>\n<strong>Major Topics:<\/strong>\n<\/p>\n<ul>\n<li>\nService Provider Selection Process\n<\/li>\n<li>\nService Provider Perceptions and Interactions\n<\/li>\n<li>\nService Provider Performance and Loyalty\n<\/li>\n<li>\nCompany Service Quality Profiles\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>Copyright and Usage Guidelines<\/strong>\n<\/p>\n<p>\n<strong>How to Use this Report<\/strong>\n<\/p>\n<p>\n<strong>Analysis Note: Outsourcing Requirement<\/strong>\n<\/p>\n<p>\n<strong>Introduction<\/strong>\n<\/p>\n<p>\n<strong>Methodology<\/strong>\n<\/p>\n<p>\n<strong>Demographics<\/strong>\n<\/p>\n<p>\n<strong>Number of Ratings per Company<\/strong>\n<\/p>\n<p>\n<strong>Major Sections<\/strong>\n<\/p>\n<p>\n<strong>Service Provider Selection Process<\/strong>\n<\/p>\n<ul>\n<li>\nPrimary Section Takeaways\n<\/li>\n<li>\nPreferred Provider Agreements\n<\/li>\n<li>\nSelection Attributes\n<\/li>\n<li>\nUse of Outside Consultants for CRO Identification and Selection\n<\/li>\n<\/ul>\n<p>\n<strong>Service Provider Perceptions and Interactions<\/strong>\n<\/p>\n<ul>\n<li>\nPrimary Section Takeaways\n<\/li>\n<li>\nPhase II\/III Leadership, Familiarity, and Reported Use\n<\/li>\n<li>\nService Provider Preference\n<\/li>\n<li>\nService Provider Preference among Users\n<\/li>\n<li>\nCost Perceptions\n<\/li>\n<li>\nCost Experience among Users\n<\/li>\n<li>\nSummary Table\n<\/li>\n<\/ul>\n<p>\n<strong>Service Provider Performance and Loyalty<\/strong>\n<\/p>\n<ul>\n<li>\nPrimary Section Takeaways\n<\/li>\n<li>\nBudget Factors\n<\/li>\n<li>\nDelivery Factors\n<\/li>\n<li>\nStaff Characteristics\n<\/li>\n<li>\nServices\n<\/li>\n<li>\nA Note on Harvey Ball Calculations\n<\/li>\n<li>\nPerformance Across Service Providers\n<\/li>\n<li>\nBudget Factors\n<\/li>\n<li>\nDelivery Factors\n<\/li>\n<li>\nStaff Characteristics\n<\/li>\n<li>\nServices\n<\/li>\n<li>\nCustomer Loyalty: 2022\n<\/li>\n<li>\nCustomer Loyalty: 3-Year Rolling Average\n<\/li>\n<\/ul>\n<p>\n<strong>Company Service Quality Profiles<\/strong>\n<\/p>\n<p>\n<strong>Study Data<\/strong>\n<\/p>\n<ul>\n<li>\nPhase II\/III Leaders, Unprompted\n<\/li>\n<li>\nOther Responses\n<\/li>\n<li>\nPhase II\/III Leaders, Prompted\n<\/li>\n<li>\nService Provider Familiarity\n<\/li>\n<li>\nService Provider Familiarity &#8211; Additional Providers\n<\/li>\n<li>\nService Provider Reported Usage\n<\/li>\n<li>\nService Provider Preference\n<\/li>\n<li>\nService Provider Differentiation\n<\/li>\n<li>\nService Provider Cost Perceptions\n<\/li>\n<li>\nUse of Preferred Providers\n<\/li>\n<li>\nNumber of Preferred Providers\n<\/li>\n<li>\nSelection Drivers: Selecting among Preferred Providers\n<\/li>\n<li>\nPreferred Provider Attributes Gaining Importance\n<\/li>\n<li>\nSelection Drivers: When Not Using Preferred Providers\n<\/li>\n<li>\nSelection Drivers: No Preferred Providers\n<\/li>\n<li>\nService Provider Attributes Gaining Importance: No Preferred Providers\n<\/li>\n<li>\nUse of Outside Consultants for CRO Identification and Selection\n<\/li>\n<li>\nService Provider Drill-downs\n<\/li>\n<li>\nAdvanced Clinical\n<\/li>\n<li>\nBiorasi\n<\/li>\n<li>\nClinipace\n<\/li>\n<li>\nClintec\n<\/li>\n<li>\nCovance\/Labcorp\n<\/li>\n<li>\nCTI Clinical Trial &amp; Consulting\n<\/li>\n<li>\nDCRI-Duke\n<\/li>\n<li>\nEurofins (including bioskin)\n<\/li>\n<li>\nFrontage\n<\/li>\n<li>\nGeorge Clinical\n<\/li>\n<li>\nICON (including PRA)\n<\/li>\n<li>\nInnovaderm\n<\/li>\n<li>\nIQVIA\n<\/li>\n<li>\nLambda\n<\/li>\n<li>\nMedpace\n<\/li>\n<li>\nMMS Holdings\n<\/li>\n<li>\nNovotech\n<\/li>\n<li>\nOra\n<\/li>\n<li>\nParexel\n<\/li>\n<li>\nPharm-Olam International\n<\/li>\n<li>\nPharPoint\n<\/li>\n<li>\nPPD\n<\/li>\n<li>\nPrecision for Medicine\n<\/li>\n<li>\nPremier Research\n<\/li>\n<li>\nPSI\n<\/li>\n<li>\nQPS\n<\/li>\n<li>\nRho\n<\/li>\n<li>\nSGS Life Sciences\n<\/li>\n<li>\nSyneos Health (including Synteract)\n<\/li>\n<li>\nUBC\n<\/li>\n<li>\nWorldwide Clinical Trials\n<\/li>\n<\/ul>\n<p>\n<strong>Demographics<\/strong>\n<\/p>\n<ul>\n<li>\nCompany Size\n<\/li>\n<li>\nOffice Location\n<\/li>\n<li>\nJob Title\n<\/li>\n<li>\nDecision-making Responsibility\n<\/li>\n<li>\nOutsourcing Involvement by Phase\n<\/li>\n<li>\nInvolvement in Clinical Development\n<\/li>\n<li>\nTherapeutic Areas of Responsibility\n<\/li>\n<li>\nYears of Industry Experience\n<\/li>\n<\/ul>\n<p>\n<strong>About the Publisher<\/strong>\n<\/p>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5697514\/phase-iiiii-cro-benchmarking-14th-ed?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=b4p29f&amp;utm_campaign=1807956+-+Global+Phase+II%2FIII+CRO+Benchmarking+Report+2022%3A+Analysis+of+CRO+Selection+and+Share+Performance+Data+for+31+Providers+on+21+Key+Attributes&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/hvbdv9<\/a>\n<\/p>\n<p>\n<strong>About ResearchAndMarkets.com<\/strong>\n<\/p>\n<p>\nResearchAndMarkets.com is the world&#8217;s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;&#111;&#x3a;p&#114;&#x65;s&#x73;&#x40;&#114;&#x65;s&#101;&#x61;r&#x63;&#x68;&#97;&#x6e;d&#109;&#x61;&#114;&#x6b;e&#116;&#x73;&#46;&#99;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;e&#115;&#x73;&#64;&#114;&#x65;s&#x65;&#x61;&#114;&#x63;h&#97;&#x6e;d&#109;&#x61;r&#x6b;&#x65;&#116;&#x73;&#x2e;&#99;&#x6f;m<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Phase II\/III CRO Benchmarking (14th Ed.)&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Although the landscape for outsourcing clinical research changes with each passing year, the goal of our CRO benchmarking reports remains the same: to help sponsors make educated decisions and to help CROs understand how they stack up against competitors on &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52936","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Phase II\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Phase II\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Phase II\/III CRO Benchmarking (14th Ed.)&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Although the landscape for outsourcing clinical research changes with each passing year, the goal of our CRO benchmarking reports remains the same: to help sponsors make educated decisions and to help CROs understand how they stack up against competitors on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-16T12:02:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230116005296\/en\/1686464\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Phase II\\\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2023-01-16T12:02:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/\"},\"wordCount\":781,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005296\\\/en\\\/1686464\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/\",\"name\":\"Global Phase II\\\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005296\\\/en\\\/1686464\\\/21\\\/logo.jpg\",\"datePublished\":\"2023-01-16T12:02:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005296\\\/en\\\/1686464\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005296\\\/en\\\/1686464\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Phase II\\\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Phase II\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Phase II\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Phase II\/III CRO Benchmarking (14th Ed.)&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. Although the landscape for outsourcing clinical research changes with each passing year, the goal of our CRO benchmarking reports remains the same: to help sponsors make educated decisions and to help CROs understand how they stack up against competitors on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-16T12:02:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230116005296\/en\/1686464\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Phase II\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes &#8211; ResearchAndMarkets.com","datePublished":"2023-01-16T12:02:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/"},"wordCount":781,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230116005296\/en\/1686464\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/","name":"Global Phase II\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230116005296\/en\/1686464\/21\/logo.jpg","datePublished":"2023-01-16T12:02:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230116005296\/en\/1686464\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230116005296\/en\/1686464\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-phase-ii-iii-cro-benchmarking-report-2022-analysis-of-cro-selection-and-share-performance-data-for-31-providers-on-21-key-attributes-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Phase II\/III CRO Benchmarking Report 2022: Analysis of CRO Selection and Share Performance Data for 31 Providers on 21 Key Attributes &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52936"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52936\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}